Aaron Hansen
University of Toronto
H-index: 49
North America-Canada
Top articles of Aaron Hansen
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial | Investigational New Drugs | Andrew J Armstrong Ravit Geva Hyun Cheol Chung Charlotte Lemech Wilson H Miller Jr | 2024/2/7 |
First-in-Human 212Pb-PSMA-Targeted α-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer | Journal of nuclear medicine: official publication, Society of Nuclear Medicine | Matthew R Griffiths David A Pattison Melissa Latter Kevin Kuan Stephen Taylor | 2024/2/29 |
Transoral Robotic Surgery and Radiation Volume Deintensification in Unknown Primary Squamous Cell Carcinoma of the Neck: The Phase 2 FIND Nonrandomized Controlled Trial | JAMA Otolaryngology–Head & Neck Surgery | John R de Almeida Rosemary Martino Ali Hosni David P Goldstein Scott V Bratman | 2024/4/11 |
Comparison of outcomes for Hispanic and non‐Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database | Cancer | Kripa Guram Jiaming Huang Christian Mouchati Nour Abdallah Chinmay Jani | 2024/1/31 |
Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck | Cell Death & Differentiation | Enrique Sanz-Garcia Jinfeng Zou Lisa Avery Anna Spreafico John Waldron | 2024/2/26 |
Understanding the incidence, duration, and severity of symptoms through daily symptom monitoring among frail and non-frail older patients receiving metastatic prostate cancer … | Journal of Geriatric Oncology | Milothy Parthipan Gregory Feng Henriette Breunis Narhari Timilshina Urban Emmenegger | 2024/4/1 |
Early changes in tumor-naive cell-free methylomes and fragmentomes predict outcomes in pembrolizumab-treated solid tumors | Cancer Discovery | Eric Y Stutheit-Zhao Enrique Sanz-Garcia Zhihui Liu Derek Wong Kayla Marsh | 2024/2/23 |
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors | Investigational New Drugs | Maxime Chénard-Poirier Aaron R Hansen Martin E Gutierrez Drew Rasco Yan Xing | 2024/3/14 |
Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer … | Clinical Genitourinary Cancer | Jeffrey Graham Sunita Ghosh Rodney H Breau Lori Wood Simon Tanguay | 2024/2/23 |
The Survival Outcomes of the Metastatic Nonclear Cell Renal Cell Carcinoma in the Immunotherapy Era: Princess Margaret Cancer Centre Experience | Journal of Kidney Cancer and VHL | Esmail Al-Ezzi Abhenil Mittal Zachary W Veitch Amer Zahralliyali Nely Mercy Diaz Mejia | 2024/3/2 |
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors | Cancer Immunology, Immunotherapy | John F Hilton Patrick A Ott Aaron R Hansen Zujun Li Matthen Mathew | 2024/2/13 |
Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma | Molecular cancer therapeutics | Cha Len Lee Grainne M O'Kane Warren P Mason Wen-Jiang Zhang Pavlina Spiliopoulou | 2024/3/1 |
Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium | European Journal of Cancer | Emanuel Bührer David D'Haese Gedske Daugaard Ronald de Wit Costantine Albany | 2024/5/1 |
Efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck: the phase 2 CheckMate … | Clinical Cancer Research | Nizar M Tannir Sabina Signoretti Toni K Choueiri David F McDermott Robert J Motzer | 2021/1/1 |
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) | Journal for immunotherapy of cancer | Sophie Postel-Vinay Vincent K Lam Willeke Ros Todd M Bauer Aaron R Hansen | 2023 |
Characterization of patients with metastatic renal cell carcinoma experiencing complete response to first-line therapies: results from the International Metastatic Renal Cell … | The Journal of Urology | Kosuke Takemura Vishal Navani Matthew S Ernst J Connor Wells Luis Meza | 2023/4 |
Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients | European Journal of Cancer | Kirsty Taylor Jinfeng Zou Marcos Magalhaes Marc Oliva Anna Spreafico | 2023/7/1 |
1313MO Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with … | Annals of Oncology | B Besse A Italiano S Cousin G Ruiter E Felip | 2023/10/1 |
Impact of treatment on elder-relevant physical function and quality of life outcomes in older adults with metastatic castration-resistant prostate cancer | Journal of Geriatric Oncology | Helen Yang Valerie S Kim Narhari Timilshina Henriette Breunis Urban Emmenegger | 2023/1/1 |
Abstract P6-10-13: An update to a Phase I trial of CFI-402257, an oral TTK inhibitor, in patients with advanced solid tumors with HER2-negative breast cancer expansion cohorts | Cancer Research | John Hilton Daniel Renouf David W Cescon Aaron Hansen Alibiruni Abdul Razak | 2023/3/1 |
